Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives Consensus Recommendation of “Hold” from Analysts

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has earned a consensus rating of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $5.00.

Several research analysts have weighed in on CTXR shares. Wall Street Zen lowered Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Zacks Research upgraded Citius Pharmaceuticals to a “hold” rating in a report on Tuesday, May 19th. Citigroup reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Wednesday, June 24th. Finally, HC Wainwright restated a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, August 19th.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in CTXR. XTX Topco Ltd bought a new stake in Citius Pharmaceuticals during the second quarter worth $32,000. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals during the second quarter worth approximately $40,000. Asset Advisory Group Inc. bought a new stake in Citius Pharmaceuticals in the fourth quarter valued at approximately $46,000. BlackRock Inc. bought a new stake in Citius Pharmaceuticals in the second quarter valued at approximately $42,000. Finally, Heights Capital Management Inc. acquired a new stake in shares of Citius Pharmaceuticals in the fourth quarter valued at approximately $622,000. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Stock Up 4.9%

Citius Pharmaceuticals stock opened at $0.60 on Wednesday. The company’s 50 day simple moving average is $0.59 and its 200 day simple moving average is $0.68. Citius Pharmaceuticals has a fifty-two week low of $0.47 and a fifty-two week high of $2.19. The firm has a market capitalization of $16.57 million, a price-to-earnings ratio of -0.36 and a beta of 1.03. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.84 and a quick ratio of 0.40.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its earnings results on Friday, August 14th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. As a group, sell-side analysts anticipate that Citius Pharmaceuticals will post -2.03 EPS for the current year.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.